VANCOUVER, Jan. 17, 2019 /CNW/ - INVICTUS MD
STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX:
IVITF; FRA: 8IS1) is pleased to announce that it has
submitted its application to list its common shares (the
"Shares") on the NASDAQ Capital Market ("NASDAQ"). In
advance of listing on NASDAQ, the Company will file a Form 40-F
Registration Statement with the United States Securities and
Exchange Commission. The listing of the Company's Shares on NASDAQ
remains subject to the approval of NASDAQ and the satisfaction of
all applicable listing and regulatory requirements, including the
effectiveness of the Form 40-F Registration Statement.
Subject to approval for listing, it is anticipated that the
Company's Shares, including the existing Shares trading on the
OTCQX under the ticker symbol "IVITF", will trade on NASDAQ under
the ticker symbol "INV". The Company's Shares will continue to
trade on the TSXV under the ticker symbol "GENE" and on the
Frankfurt Stock Exchange under the ticker symbol "8IS1". A trading
date will be made public once all regulatory formalities are
satisfied.
In connection with the listing on NASDAQ, the Company also
announces it will be proceeding with a consolidation of its issued
and outstanding common shares (the "Consolidation") on the
basis of one post-Consolidation Share for every seven
pre-Consolidation Shares. No fractional Shares will be
issued. Any fractional Share will be rounded down to the
nearest whole number.
The Consolidation is subject to final confirmation by the TSX
Venture Exchange (the "TSXV"). As a result of the
Consolidation, the 112,176,712 Shares which are currently issued
and outstanding will be reduced to approximately 16,025,244 Shares,
subject to rounding.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
George E. Kveton
Chief Executive Officer and Director
Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(833) 879-4363
About Invictus
Invictus is a global cannabis company offering a selection of
products under a wide range of brands. Our integrated sales
approach is defined by five pillars of distribution including
medical, adult-use, international, Licensed Producer to Licensed
Producer and retail stores.
Invictus has partnered with business leaders to convey our
corporate vision, including KISS music legend and business mogul
Gene Simmons as our Chief Evangelist
Officer. To meet growing demand, Invictus is expanding its
cultivation footprint, with three cannabis production facilities
licensed under the Cannabis Act and Cannabis Regulations in
Canada. To accommodate
international sales, Invictus' wholly-owned subsidiary, Acreage
Pharms Ltd. ("Acreage Pharms"), has designed and is currently
building its Phase 3 purpose-built cultivation facility to be
European Union Good Manufacturing Practices ("EU-GMP") compliant.
The Company is targeting up to 50 percent of production to medical
cannabis. To ensure consistency in quality and supply, Invictus
maintains all aspects of the growing process through its
subsidiary, Future Harvest Development Ltd. ("Future Harvest"), a
high-quality fertilizer and nutrients manufacturer. Invictus drives
sustainable long-term shareholder value through a diversified
product portfolio with over 70 Health Canada approved strains and a
multifaceted distribution strategy including medical, adult-use,
international, Licensed Producer to Licensed Producer and retail
stores. For more information visit www.invictus-md.com.
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements
within the meaning of the United States Private Securities
Litigation Reform Act of 1995. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, timing, assumptions
or expectations of future performance, including statements with
respect to the consolidation of the Company's common shares; and
the timing, receipt of regulatory approval for, and listing of the
Company's common shares on NASDAQ and the filing of a Form 40-F
Registration Statement with the United States Securities and
Exchange Commission are forward-looking statements and contain
forward-looking information. Generally, forward-looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including that the Company will be successful in completing
the consolidation and obtaining NASDAQ approval and all necessary
regulatory approvals for the listing of its common shares on
NASDAQ. These forward-looking statements are subject to known and
unknown risks, uncertainties and other factors that may cause the
actual results, level of activity, performance or achievements of
the Company to be materially different from those expressed or
implied by such forward-looking statements or forward-looking
information. Important factors that may cause actual results to
vary, include, without limitation, the Company will not be
successful in completing the Consolidation or obtaining the
necessary regulatory approvals to complete the listing on NASDAQ.
Although management of the Company has attempted to identify
important factors that could cause actual results to differ
materially from those contained in forward-looking statements or
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements and
forward-looking information. Readers are cautioned that reliance on
such information may not be appropriate for other purposes. The
Company does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/invictus-md-announces-submission-of-its-application-to-list-on-nasdaq-and-share-consolidation-300780198.html
SOURCE Invictus MD Strategies